REFERENCES
- Anderson AC. (2012). Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol, 24, 213–16
- Anderson AC, Anderson DE, Bregoli L, et al. (2007). Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science, 318, 1141–3
- Anderson AC, Lord GM, Dardalhon V, et al. (2010). T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol, 40, 859–66
- Dardalhon V, Anderson AC, Karman J, et al. (2010). Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 185, 1383–92
- da Silva IP, Gallois A, Jimenez-Baranda S, et al. (2012). Tim-3 expression and function in natural killer cells from advanced melanoma patients. Cancer Res, 72, 5410
- Fourcade J, Sun Z, Benallaoua M, et al. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med, 207, 2175–86
- Frisancho-Kiss S, Nyland JF, Davis SE, et al. (2006). Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol, 176, 6411–15
- Gao X, Zhu Y, Li G, et al. (2012). TIM-3 expression characterizes regulatory t cells in tumor tissues and is associated with lung cancer progression. PLoS One, 7, 30676
- Gleason MK, Lenvik TR, McCullar V, et al. (2012). Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood, 119, 3064–72
- Huang X, Bai X, Cao Y, et al. (2010). Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med, 207, 505–2
- Ju Y, Hou N, Meng J, et al. (2010). T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol, 52, 322–9
- McIntire JJ, Umetsu SE, Akbari O, et al. (2001). Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol, 2, 1109–16
- Monney L, Sabatos CA, Gaglia JL, et al. (2002). Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 415, 536–41
- Nakae S, Iikura M, Suto H, et al. (2007). TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood, 110, 2565–8
- Ndhlovu LC, Lopez-Vergès S, Barbour JD, et al. (2012). Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood, 119, 3734–43
- Oikawa T, Kamimura Y, Akiba H, et al. (2006). Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol, 177, 4281–7
- Sakuishi K, Apetoh L, Sullivan JM, et al. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 207, 2187–94
- Sánchez-Fueyo A, Tian J, Picarella D, et al. (2003). Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol, 4, 1093–101
- Yang ZZ, Grote DM, Ziesmer SC, et al. (2012). IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest, 122, 1271–82
- Zhou Q, Munger ME, Veenstra RG, et al. (2011). Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 117, 4501–10
- Zhu C, Aderson AC, Schubart A, et al. (2005). The Tim-3 ligand galectin-9 negatively regulates T helper type I immunity. Nat Immunol, 6, 1245
- Zou W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 5, 263–74